Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Impact of guideline-discordant care for muscle-invasive bladder cancer on preventable survival losses: A national counterfactual analysis of 55,873 patients.

Shivam Chetankumar Patel, Pragya Jain, Ansy Patel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16586

e16586 Background: Guideline-discordant care disproportionately affects racial minorities, uninsured, and underinsured pat...

Failure-to-rescue after pancreatectomy for pancreatic cancer in the United States: National Inpatient outcomes, 2018–2023.

Tajveer Sangha, Aishwarya Hanspal, Arman Manjikian et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23232

e23232 Background: Pancreatectomy for pancreatic cancer carries substantial postoperative morbidity. As operative mortalit...

Appendiceal cancer: Historical trends in histological composition and cause-specific mortality based on SEER database analysis.

Jamil Qiqieh, Cameron Peres, Essam Al-Snayyan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16485

e16485 Background: Appendiceal cancers are rare malignancies characterized by marked histologic heterogeneity and diverse...

An emerging disparity in young-onset lung adenocarcinoma: Evidence from a SEER analysis.

Hnada Nader Samaan, Sohaib Al Omari, Sara Saed Fakeh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20677

e20677 Background: Lung adenocarcinoma (LUAD) incidence in younger adults has received limited attention, and stage-specif...

Impact of mRNA SARS-CoV-2 vaccination on CAR T-cell therapy outcomes in hematologic malignancies: A multi-center real-world analysis.

Jowan Al-Nusair, Mohanad Elchouemi, Mostafa Eysha et al. Jun 01, 2026 pp. 11001-11001 10.1200/jco.2026.44.16_suppl.11001

11001 Background: The clinical landscape of hematologic malignancies has been reshaped by Chimeric Antigen Receptor (CAR)...

Patterns of upper endoscopy use prior to gastric cancer diagnosis among high-risk populations.

Rohit Khullar, Xiaocen Zhang, Sonia Friedman Jun 01, 2026 pp. 11192-11192 10.1200/jco.2026.44.16_suppl.11192

11192 Background: Gastric cancer is frequently diagnosed at advanced stages in the United States, contributing to poor sur...

Separating facts from feeds: An evaluation of social media videos on Barrett’s esophagus.

Sean Bowden, Sankirth Madabhushi, Gazal Gulati et al. Jun 01, 2026 pp. 9043-9043 10.1200/jco.2026.44.16_suppl.9043

9043 Background: Esophageal cancer is subdivided into two types based on histopathology, squamous cell carcinoma and adeno...

Effect of induction immunochemotherapy before concurrent chemoradiotherapy on outcomes in limited-stage small cell lung cancer.

Letong Yang, Di Liu, Min Hu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20158

e20158 Background: Immunotherapy, chemotherapy, and radiotherapy all play significant roles in the management of small cel...

Clinical efficacy and tolerability of the selective RET inhibitor soxataltinib (SY-5007) in advanced <i>RET</i> fusion–positive non–small cell lung cancer (NSCLC): Primary findings from a confirmatory phase III trial.

Anwen Xiong, Xiangjiao Meng, Yongzhong Luo et al. Jun 01, 2026 pp. 8639-8639 10.1200/jco.2026.44.16_suppl.8639

8639 Background: Oncogenic RET gene fusions represent a clinically validated molecular driver occurring in approximately 1...

10-year molecular landscape of metastatic colorectal cancer in Latin America: Gender and age-specific mutational patterns in a large Colombian cohort (N=2,543).

Carolina Lopez Ordoñez, Ruby Rios, Iván Bravo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15597

e15597 Background: Molecular profiling of KRAS , NRAS...

BRIDGe: Barriers to real-world implementation of diagnostic genomics—Quantifying the genomic awareness-access divide in Indian oncology care.

Vishwanath Sathyanarayanan, Narendhar Gokulanathan, Jahnavi Peddireddy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13604

e13604 Background: Uptake and actionability of molecular testing remain suboptimal in low-and-middle-income settings. In t...

Phase II study of frontline gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) in advanced urachal and non-urachal urinary tract adenocarcinoma.

Emanuele Crupi, Jianjun Gao, Paul Gettys Corn et al. Jun 01, 2026 pp. 4515-4515 10.1200/jco.2026.44.16_suppl.4515

4515 Background: Adenocarcinomas of the urinary tract are rare malignancies with limited prospective data. Outcomes of tri...

Enrollment outcomes after screening in phase 1 oncology clinical trials: Real-world evidence from a NCI-designated cancer center.

Erica DeCecco, Reema Mody, Narjust Florez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13720

e13720 Background: Despite many efforts to increase diversity enrollment in Phase 1 trials (Ph1) significant disparities p...

The association of nutritional factors on disease control and survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) treated with anti–PD-1 monoclonal antibody.

Jessica Zheng, Lufeiya Liu, Hong Wang et al. Jun 01, 2026 pp. 6053-6053 10.1200/jco.2026.44.16_suppl.6053

6053 Background: Anti-PD-1 mAb therapy is standard of care for systemic treatment for R/M-HNSCC. These patients (pts) also...

Social determinants of health and survival outcomes in metastatic breast cancer (MBC): Retrospective analysis from a major Canadian cancer centre.

Anshini Shah, Richard Musoke, Jenny Yang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13758

e13758 Background: Social determines of health (SDOH), including geography and sociodemographic factors influence cancer o...

Meaning-centered psychotherapy versus dignity therapy for spiritual well-being in patients with cancer: A systematic review and meta-analysis.

Danielle Soler Lopes, Isabela Borja de Oliveira, Ana Camily Cruz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24118

e24118 Background: Meaning-Centered Psychotherapy (MCP) and Dignity Therapy (DT) are frequently employed psychotherapeutic...

Impact of adjuvant sequential chemoradiotherapy on long-term overall survival in early-stage cervical cancer: Final analysis of the STARS phase III randomized trial.

He Huang, Qidan Huang, Hua Tu et al. Jun 01, 2026 pp. 5527-5527 10.1200/jco.2026.44.16_suppl.5527

5527 Background: The STARS trial (NCT00806117) previously demonstrated that adjuvant sequential chemoradiotherapy (SCRT) s...

Impact of ILT4 on lipid metabolism of tumor-associated macrophages to drive immunosuppression and tumor progression in NSCLC.

Shuyun Wang, Yihui Ge, Xuebing Fu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20598

e20598 Background: Tumor-associated macrophages (TAMs), as the most abundant immune cells in the tumor microenvironment (T...

The impact of adjusting for c-Kit exon 11 mutation status when comparing prognostic models for gastrointestinal stromal tumors for prediction of recurrence.

Christina Carfagnini, Chenyu Sun, Rishi Bothara et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23510

e23510 Background: There is minimal data comparing the prognostic models (PM) developed to predict recurrence of Gastroint...

Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in triple-negative breast cancer: A systematic review and meta-analysis.

Haseeb Tareen, Allah Dad, Muhammad Arham et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13121

e13121 Background: Triple-negative breast cancer (TNBC) lacks reliable prognostic biomarkers beyond standard clinical stag...

Trends and disparities in cerebrovascular disease–related mortality in patients with chronic lymphocytic leukemia: A retrospective analysis across two decades.

Haadia Rafiq, Elangovan Krishnan, Sophia Ahmed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18633

e18633 Background: Cerebrovascular disease (CVD) is an important cause of morbidity and mortality in patients with chronic...

Health technology agencies' reimbursement decisions for cancer drugs across four high-income countries.

Mina Jordanides, Sophie Keith-Brown, Kristina Jenei et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23037

e23037 Background: For people with advanced cancer, alternative endpoints such as progression-free survival (PFS) often co...

Association of gut microbiota and peri-initiation proton pump inhibitor/antibiotic exposure with outcomes of atezolizumab-bevacizumab-carboplatin-paclitaxel regimen in patients with advanced non-squamous NSCLC: Prospective phase II study (K-TAIL-201).

Hiroshi Wakui, Takahiro Yoshizawa, Sojiro Kusumoto et al. Jun 01, 2026 pp. 8541-8541 10.1200/jco.2026.44.16_suppl.8541

8541 Background: Concomitant medications that alter gut microbiome composition, such as proton pump inhibitors (PPIs) and...

Long-term survival, disparities, and future burden of multiple myeloma: A population-based analysis.

Sameer Krishna Prasad Garlapati, Madho Mal, Nayanika Chowdary Tummala et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19562

e19562 Background: Multiple myeloma is a chronic blood cancer in which patients often live for many years, yet the risk of...

Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics.

Hiroyuki Yamamoto, Hideaki Bando, Yoshiaki Nakamura et al. Jun 01, 2026 pp. 3501-3501 10.1200/jco.2026.44.16_suppl.3501

3501 Background: While ACT is recommended by clinical guidelines for patients (pts) with high-risk stage II and stage III...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page